We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy.
- Authors
Li, Yufeng; Wang, Chun-ling; Din, Banhe; Yu, Liang; Zhu, Jiabin
- Abstract
The article presents a study that outlines the individual therapy options for patients with different grades of adverse event (AE) following imatinib (IM) as the first-line treatment through the precise definition of IM intolerance. It examines the hematologic, cytogenetic, and molecular responses to IM at the end of the third, sixth, and twelfth months. A conventional cytogenetic analysis of bone marrow metaphase cells has been used to assess cytogenetic responses.
- Subjects
IMATINIB; ADVERSE health care events; LEUKEMIA treatment; MYELOID leukemia; CYTOGENETICS; PATIENTS
- Publication
Acta Haematologica, 2017, Vol 137, Issue 3, p158
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000455035